Centessa Pharmaceuticals (CNTA) AI Stock Analysis

• Market Cap: $3.36B
• Dividend Yield: N/A
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: 117.83%
• EPS Growth: -18.91%
• Country: US
• Employees: 77
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 146,075,740
• 10 Day Avg. Volume: 1,783,469
• 30 Day Avg. Volume: 1,274,948
• PEG Ratio: -0.26
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.49
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 215.45
• Enterprise Value/Gross Profit: 218.78
• Enterprise Value/Ebitda: -14.22
• 1Y Price Target: $39.55
• Price Target Upside: 58.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $22.00 ▼(-12.00% Downside)

The score is held down primarily by weak financial performance (large ongoing losses and significant cash burn on limited revenue) and bearish/weak technicals (below key moving averages with negative MACD). Corporate events add some support via improved capital-raising flexibility and leadership/strategy updates, but they do not fully offset the underlying profitability and cash-consumption risks.

Positive Factors

Clinical-stage pipeline progress (OX2R agonists)

Advancing ORX750 into a registrational program marks a structural de-risking milestone for Centessa’s neuroscience franchise. Moving from exploratory to registrational trials increases the likelihood of later regulatory value creation and directs R&D resources toward a coherent, higher-priority commercial pathway over the next 2–3 years.

High reported gross profitability

Sustained gross margins near 94% indicate collaboration and product-related revenues incur low direct costs, implying that if Centessa converts pipeline successes to recurring sales or higher-value licensing, incremental revenue could flow to the bottom line efficiently and support long-term margin sustainability once commercialized.

Improved funding flexibility via ATM amendment

Access to a $250M ATM increases strategic optionality to smooth financing over time, reducing acute refinancing risk. For a clinical-stage biotech with ongoing trials, this structural flexibility helps maintain program funding, enabling multi-year R&D plans without forcing large, single-event capital raises.

Negative Factors

Large and persistent cash burn

Very negative operating and free cash flow reflects ongoing funding of multiple clinical programs and is a durable constraint on the business. Continued burn necessitates periodic external financing, increasing execution risk if capital markets tighten and potentially delaying programs if funding is constrained.

Deep unprofitability and negative margins

Large operating losses show the company is far from self-sustaining while clinical-stage, meaning profitability depends on successful clinical outcomes and future commercialization. This structural deficit limits reinvestment capacity and increases reliance on external capital to fund R&D and regulatory milestones over the medium term.

Equity erosion and ongoing dilution risk

Declining equity alongside heavy losses signals cumulative dilution and capital consumption. Coupled with recent ADS offerings and ATM capacity, shareholders face structural dilution risk as the company repeatedly taps markets to fund operations until products generate sustainable cash flow.

Centessa Pharmaceuticals Business Overview & Revenue Model

Company Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

How the Company Makes Money

Centessa Pharmaceuticals generates revenue primarily through the research and development of novel drug candidates, which it aims to bring to market either independently or through strategic partnerships. The company invests in early-stage and clinical development of drug candidates, seeking to advance them through the pipeline to commercialization. Revenue streams are expected to include sales of approved therapies, milestone payments, and royalties from collaborations with larger pharmaceutical companies. Additionally, Centessa may engage in licensing agreements that provide upfront payments and future royalties, contingent upon the success of its drug candidates in clinical trials and eventual market approval.

Centessa Pharmaceuticals Financial Statement Overview

Summary

Financials are dominated by heavy losses and cash burn (TTM EBIT -$213.8M; net loss -$242.7M; operating cash flow -$180.8M; FCF -$181.2M) on modest TTM revenue of $15.0M. The balance sheet is a relative support (debt-to-equity ~0.34), but equity has declined, reinforcing ongoing financing/dilution risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is modest at $15.0M with very high gross profitability (~94%), but the company remains deeply unprofitable (EBIT of -$213.8M; net loss of -$242.7M) with extremely negative net margins. Revenue has not meaningfully grown in the TTM period, and prior years show limited/uneven revenue generation, reinforcing that earnings power is still not established.

Balance Sheet

The balance sheet shows moderate leverage with debt at $118.3M against $301.6M of equity (debt-to-equity ~0.34), which is reasonable for a development-stage biotech. However, equity has declined versus the prior annual period ($401.5M to $301.6M), consistent with ongoing losses, and returns on equity remain sharply negative—highlighting continued capital consumption risk.

Cash Flow

Cash generation is a clear weakness: TTM (Trailing-Twelve-Months) operating cash flow is -$180.8M and free cash flow is -$181.2M, indicating heavy ongoing cash burn. A positive free-cash-flow growth figure reflects reduced burn versus earlier periods rather than sustainably positive cash flow, and cash outflows remain broadly in line with reported losses—suggesting continued dependence on external funding over time.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.00M	0.00	6.85M	0.00	0.00	0.00
Gross Profit	14.77M	0.00	6.85M	0.00	0.00	0.00
EBITDA	-227.27M	-221.88M	-165.43M	-209.55M	-139.30M	-10.29M
Net Income	-242.70M	-235.76M	-151.09M	-216.21M	-381.90M	-10.66M
Balance Sheet
Total Assets	448.30M	576.80M	360.25M	444.31M	629.63M	11.72M
Cash, Cash Equivalents and Short-Term Investments	246.21M	482.18M	256.55M	393.64M	595.08M	7.23M
Total Debt	118.26M	117.23M	84.59M	69.80M	75.70M	5.63M
Total Liabilities	146.73M	175.25M	124.00M	108.14M	138.08M	8.62M
Stockholders Equity	301.57M	401.55M	236.24M	336.17M	491.55M	3.10M
Cash Flow
Free Cash Flow	-181.17M	-142.09M	-160.51M	-201.68M	-136.33M	-10.63M
Operating Cash Flow	-180.81M	-142.06M	-160.34M	-200.55M	-136.14M	-10.63M
Investing Cash Flow	-175.40M	31.27M	-127.00M	-931.00K	63.25M	0.00
Financing Cash Flow	11.09M	364.75M	21.12M	457.00K	660.07M	1.36M

Centessa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTA, the sentiment is Positive. The current price of 25 is above the 20-day moving average (MA) of 23.81, below the 50-day MA of 25.59, and above the 200-day MA of 19.67, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 53.38 is Neutral, neither overbought nor oversold. The STOCH value of 58.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTA.

Centessa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XENE	59 Neutral	$3.18B	-10.40	-45.14%	―	―	-38.30%
IMVT	56 Neutral	$5.07B	-8.50	-95.93%	―	―	-27.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLS	50 Neutral	$2.93B	75.99	14.10%	―	42.11%	―
SRRK	50 Neutral	$4.78B	-13.67	-218.04%	―	―	-31.71%
CNTA	48 Neutral	$3.36B	-12.93	-60.45%	―	117.83%	-18.91%
RARE	47 Neutral	$2.38B	-4.01	-325.76%	―	20.63%	8.09%

Centessa Pharmaceuticals Corporate Events

Centessa Pharmaceuticals Appoints New CEO Amid Strategic Shift

On December 11, 2025, Centessa Pharmaceuticals announced the appointment of Dr. Mario Alberto Accardi as the new Chief Executive Officer, effective January 1, 2026. Dr. Accardi, who has been instrumental in leading Centessa’s Orexin Program, will succeed Dr. Saurabh Saha, who will transition to an advisory role. This leadership change marks a strategic shift for Centessa, as it intensifies its focus on advancing its orexin portfolio, particularly OX2R agonists, which are poised to address a range of neurological disorders. The company aims to capitalize on the promising growth opportunities in neuroscience, with key milestones expected in 2026, positioning itself at the forefront of this emerging therapeutic class.

The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.

Centessa Pharmaceuticals Amends Sales Agreement for Flexibility

On November 24, 2025, Centessa Pharmaceuticals amended its Sales Agreement with Leerink Partners LLC, allowing the company to issue and sell up to $250 million of its American Depositary Shares through ‘at the market offerings.’ This strategic move, facilitated by Leerink as the sales agent, aims to provide Centessa with flexibility in raising capital for working capital, capital expenditures, and general corporate purposes. The agreement includes customary representations, warranties, and covenants, and does not obligate the company to sell any shares, nor does it specify a minimum offering amount. The impact of this agreement could enhance Centessa’s financial resources, potentially strengthening its market position and operational capabilities.

The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.

Centessa Pharmaceuticals Announces Underwriting Agreement for ADS Offering

On November 11, 2025, Centessa Pharmaceuticals announced an underwriting agreement to issue and sell 11,627,907 American Depositary Shares (ADSs) at $21.50 per share, with an option for underwriters to purchase an additional 1,744,186 ADSs. The offering is expected to close on November 14, 2025, and aims to raise approximately $234.4 million, potentially increasing to $269.6 million if the over-allotment option is exercised. The proceeds will fund the development of product candidates and general corporate purposes, potentially supporting operations until 2028. This move is part of Centessa’s strategy to bolster its financial resources for ongoing and future projects, thereby strengthening its position in the pharmaceutical industry.

The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.

Centessa Pharmaceuticals Reports Q3 2025 Financial Results

Centessa Pharmaceuticals reported its financial results for the third quarter of 2025 and provided updates on its orexin receptor 2 (OX2R) agonist program. The company highlighted significant progress in its clinical trials, particularly with ORX750, which showed promising results in treating narcolepsy and idiopathic hypersomnia. The Phase 2a study of ORX750 demonstrated statistically significant improvements in wakefulness and daily functioning for patients, with plans to initiate a registrational program in early 2026. Additionally, ORX142 showed a highly differentiated profile in Phase 1 trials, and ORX489 is advancing in IND-enabling studies. Financially, Centessa reported a net loss of $54.9 million for the quarter, with cash reserves expected to fund operations into mid-2027.

The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.